Breaking News Instant updates and real-time market news.

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

, BAYRY

Bayer

$0.00

(0.00%)

04:55
10/13/19
10/13
04:55
10/13/19
04:55

Healthcare Made Practical to hold a symposium

Symposium on Clinical Interventional Oncology will be held in Miami on October 11-13.

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

BAYRY

Bayer

$0.00

(0.00%)

BSX

Boston Scientific

$38.22

0.22 (0.58%)

BTG

B2Gold

$3.25

-0.2 (-5.80%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

LLY

Eli Lilly

$108.37

1.54 (1.44%)

MDT

Medtronic

$107.61

0.24 (0.22%)

PFE

Pfizer

$36.11

0.31 (0.87%)

PHG

Philips

$42.88

0.99 (2.36%)

TRUMY

Terumo

$0.00

(0.00%)

VAR

Varian Medical

$110.78

1.84 (1.69%)

  • 15

    Oct

  • 15

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 13

    Nov

ANGO AngioDynamics
$14.54

0.12 (0.83%)

10/04/19
KEYB
10/04/19
NO CHANGE
Target $21
KEYB
Overweight
AngioDynamics price target lowered to $21 from $30 at KeyBanc
KeyBanc analyst Matthew Mishan reiterated an Overweight rating on AngioDynamics but lowered his price target to $21 from $30, saying he views first quarter results as "mixed" and believes investors are focused on the dilutive acquisition of Eximo Medical. While Mishan says he still sees a path toward a sustained inflection in revenue growth, the key piece, Oncology, has not gained momentum yet.
04/01/19
KEYB
04/01/19
UPGRADE
KEYB
Overweight
AngioDynamics upgraded to Overweight from Sector Weight at KeyBanc
BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
BSX Boston Scientific
$38.22

0.22 (0.58%)

09/20/19
COWN
09/20/19
NO CHANGE
Target $47
COWN
Outperform
Boston Scientific setting up well for better second half, says Cowen
Cowen analyst Joshua Jennings said Boston Scientific is setting up for a batter second half to the year as the company has a steady flow of product launches scheduled for the second half and should also experience momentum in its core businesses over that interval. In addition, there is one more selling day in the second half versus one less in the first. Jennings reiterated his Outperform rating and $47 price target on Boston Scientific shares.
09/03/19
LEHM
09/03/19
INITIATION
Target $48
LEHM
Overweight
Boston Scientific reinstated with an Overweight at Barclays
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."
09/05/19
JPMS
09/05/19
INITIATION
Target $50
JPMS
Overweight
Boston Scientific reinstated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
09/05/19
09/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with an Equal Weight at Morgan Stanley. 2. Organigram (OGI) initiated with a Perform at Oppenheimer. 3. Wingstop (WING) initiated with a Market Perform at Raymond James. 4. Boston Scientific (BSX) reinstated with an Overweight at JPMorgan. 5. Cubic (CUB) initiated with a Hold at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BTG B2Gold
$3.25

-0.2 (-5.80%)

JNJ Johnson & Johnson
$131.35

2.32 (1.80%)

10/02/19
WELS
10/02/19
NO CHANGE
WELS
Outperform
J&J Ohio settlements suggest 'manageable' liability, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Johnson & Johnson has announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the company from the federal trial scheduled to begin October 21, 2019 for a total of $20.4M. The analyst notes that after applying the total settlement amount to the populations of Cuyahoga and Summit counties and that to the total U.S. population of 327M, he arrives at a total settlement amount of $3.7B, which is well below his expected total settlement amount of $10B-$15B. Importantly, Biegelsen expects any settlement amount to be paid over a period of many years which will make the potential payments more manageable for Johnson & Johnson. He has an Outperform rating on the shares.
10/11/19
BERN
10/11/19
UPGRADE
BERN
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Bernstein
10/11/19
BERN
10/11/19
UPGRADE
Target $155
BERN
Outperform
Bernstein upgrades 'historically cheap' Johnson & Johnson to Outperform
Bernstein analyst Lee Hambright upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $155, up from $148. The shares in premarket trading are up $1.94, or 1.5%, to $131. The stock is "historically cheap," currently trading at a 17% discount to its sum-of-the-parts and a 13% discount to the S&P 500 Index, Hambright tells investors in a research note. The analyst, who believes J&J will resolve its legal liability for $10B-$12B, says the shares reflect a worst case scenario with $50B of liabilities being priced in. Following discussions with legal experts, Hambright has a "hard time seeing the worst-case scenarios playing out." The analyst estimates Johnson & Johnson faces about $5B of liability for opioids, another $5B for talc, and $800M for Risperdal.
08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.
LLY Eli Lilly
$108.37

1.54 (1.44%)

07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
MDT Medtronic
$107.61

0.24 (0.22%)

09/27/19
PIPR
09/27/19
NO CHANGE
PIPR
Piper says insulin pump survey most positive for Insulet
Piper Jaffray analyst JP McKim conducted an insulin delivery survey in August and found that pump penetration is going "much higher" both in type 1s and in type 2s. The growth in the type 2 market is underappreciated by investors and will largely benefit Insulet (PODD) today given the pharmacy channel increases that access, McKim tells investors in a research note. Further, survey indicated that Medtronic (MDT) is expected to lose between 1,100-1,300 basis points of market share with Tandem Diabetes (TNDM) being the greatest beneficiary with the biggest uptick forecast in 2020, says the analyst. McKim views the insulin pump survey as most positive for Insulet.
09/16/19
JPMS
09/16/19
NO CHANGE
JPMS
Overweight
Medtronic one of the few that could see multiple expansion, says JPMorgan
JPMorgan analyst Robbie Marcus believes Medtronic's pipeline is "deep and often overlooked." He sees a number of "significant potential catalysts" over the coming year that he believes many investors aren't focused on. The analyst thinks investors will want to own Medtronic not only for the expected sales acceleration, from ~4% this fiscal year to ~5% in fiscal 2021, but also for the potential upside in the out-years as pipeline catalysts, that "aren't appropriately modeled by the Street," play out. Medtronic is one of the few large-cap names that could see further multiple expansion, says Marcus, who reiterates an Overweight rating on the shares.
09/25/19
GUGG
09/25/19
NO CHANGE
GUGG
Neutral
Medtronic financial projections for Hugo robot 'underwhelming,' says Guggenheim
After attending Medtronic's (MDT) "much-anticipated" robotic-assisted surgery event, where the company gave a first look at the Hugo RAS system, Guggenheim analyst Chris Pasquale noted that the company gave an update on regulatory timelines and initial revenue targets, though information on pricing and clinical comparability to Intuitive Surgical's (ISRG) da Vinci system were "notably absent." He was impressed by certain design elements, though he thinks management's financial projections for Hugo were "somewhat underwhelming," said Pasquale, who keeps a Neutral rating on Medtronic shares.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $633
PIPR
Overweight
Piper says Intuitive Surgical overhang over after Medtronic unveils Hugo
Medtronic (MDT) yesterday afternoon showcased its long-awaited multi-port surgical robot Hugo, which will compete with Intuitive Surgical's (ISRG) da Vinci, Piper Jaffray analyst Matt O'Brien tells investors in a research note. As expected, Medtronic's robot is a fully modular system with an open console design and 3D vision, says the analyst. He believes Hugo should garner interest from hospitals considering its value proposition. However, Medtronic's system is at least two years out from the U.S., and the company will not be giving the system away for free like some feared, explains O'Brien. Competition has been an overhang for Intuitive for the last several months, says O'Brien, who left yesterday "feeling A LOT better about Intuitive's competitive positioning and long term growth potential." He believes Intuitive Surgical's overhang is over and that the company is likely to remain the market leader. The analyst keeps an Overweight rating on the shares with a $633 price target. O'Brien also has an Overweight rating on Medtronic with a $120 price target.
PFE Pfizer
$36.11

0.31 (0.87%)

10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
PHG Philips
$42.88

0.99 (2.36%)

10/24/18
DBAB
10/24/18
NO CHANGE
DBAB
Philips named a Catalyst Buy at Deutsche Bank
Deutsche Bank named Philips as a Catalyst Buy, stating that it expects investors to look past the temporary slowdown in Personal Health and focus on the much stronger than expected performance of Philips' Diagnosis & Treatment division.
07/30/19
07/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with an Outperform at Oppenheimer. 2. Medallia (MDLA) initiated with an Overweight at Stephens. 3. Fanhua (FANH) initiated with an Overweight at Morgan Stanley. 4. Philips (PHG) initiated with a Buy at Citi. 5. Freshpet (FRPT) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/19
SBSH
07/30/19
INITIATION
SBSH
Buy
Philips initiated with a Buy at Citi
Citi analyst Kate Kalashnikova started Philips with a Buy rating and 49 euros price target. The expects the company's earnings momentum in diagnosis and treatment to continue as well as its recovery in personal health.
04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Masimo (MASI) to Neutral mainly on valuation concerns, stating that while nothing has changed in his positive expectations for the company's performance, the stock may be "running out of steam". The analyst believes that Masimo should continue "taking market share, post strong revenue growth supported by multiple drivers, and enjoy adoption uplift through the Philips (PHG) co-marketing deal", but also sees the valuation on the stock reflecting "a good deal of the good news".
TRUMY Terumo
$0.00

(0.00%)

VAR Varian Medical
$110.78

1.84 (1.69%)

09/12/19
EVER
09/12/19
UPGRADE
EVER
In Line
Varian Medical upgraded to In Line from Underperform at Evercore ISI
09/23/19
BRRR
09/23/19
NO CHANGE
Target $146
BRRR
Outperform
Varian Medical price target raised to $146 from $142 at Barrington
Barrington analyst Michael Petusky raised his price target for Varian Medical Systems to $146 from $142 after the company held a meeting for investors at this year's ASTRO Conference. Varian remains committed to broadening its "already significant" footprint in the cancer care space and highlighted several ways in which it will deliver value to care providers, patients and payors, Petusky tells investors in a research note. The analyst "strong" believes that the company is well positioned for any potential reimbursement changes that might come as healthcare continues to evolve towards a more value-based model. He keeps an Outperform rating on Varian Medical.
09/12/19
EVER
09/12/19
UPGRADE
Target $123.5
EVER
In Line
Evercore upgrades Varian Medical to In Line on tariff relief from China
Evercore ISI analyst Vijay Kumar upgraded Varian Medical Systems to In Line from Underperform and raised his price target for the shares to $123.50 from $122. The analyst upgraded the shares after Varian received an exemption from China relative to the tariffs on imports from the U.S. The analyst thinks Varian's earnings were hurt by 3%-4% in fiscal 2019 from the tariffs, or 15c-20c per share. However, some of the upside from the tariff relief is offset by lower organic sales assumptions and currency volatility, Kumar tells investors in a research note.
07/17/19
PIPR
07/17/19
NO CHANGE
Target $15
PIPR
Overweight
Competitor recall highlights superiority of ViewRay system, says Piper Jaffray
After a notice appeared yesterday on the FDA website indicating that Elekta had issued a recall on its Unity system, Piper Jaffray analyst Matt O'Brien said he does not want to overstate the impact of this specific recall on ViewRay's (VRAY) ability to win business, but he does think that it highlights the superiority of the MRIdian system compared to Elekta's Unity platform. The analyst, who continues to believe that ViewRay's system is superior not only to Elekta in the MRgRT space but also when compared to "the dominant player," Varian Medical (VAR), keeps an Overweight rating and $15 price target on ViewRay shares.

TODAY'S FREE FLY STORIES

SYF

Synchrony

$33.97

0.48 (1.43%)

, SLB

Schlumberger

$31.90

-0.06 (-0.19%)

20:25
10/17/19
10/17
20:25
10/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SYF

Synchrony

$33.97

0.48 (1.43%)

SLB

Schlumberger

$31.90

-0.06 (-0.19%)

AXP

American Express

$119.17

1.76 (1.50%)

KO

Coca-Cola

$53.80

0.31 (0.58%)

STT

State Street

$59.71

0.57 (0.96%)

CFG

Citizens Financial

$35.01

-0.12 (-0.34%)

KSU

Kansas City Southern

$135.33

1.04 (0.77%)

GNTX

Gentex

$27.57

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 13

    Nov

  • 06

    Dec

PLSE

Pulse Biosciences

$14.52

0.525 (3.75%)

20:10
10/17/19
10/17
20:10
10/17/19
20:10
Hot Stocks
Pulse Biosciences to present data from studies of nano-pulse stimulation at ASDS »

Pulse Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TW

Tradeweb Markets

$43.20

0.87 (2.06%)

19:50
10/17/19
10/17
19:50
10/17/19
19:50
Syndicate
Tradeweb Markets 17.29M share Secondary priced at $42.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

SWDAF

Software AG

$0.00

(0.00%)

19:33
10/17/19
10/17
19:33
10/17/19
19:33
Upgrade
Software AG rating change at Goldman Sachs »

Software AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.43

-0.22 (-1.50%)

18:57
10/17/19
10/17
18:57
10/17/19
18:57
Hot Stocks
Petrobras reports Q3 production 2.878M boepd, up 9.3% »

Petrobras said it posted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MRTN

Marten Transport

$21.52

0.31 (1.46%)

, ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

18:49
10/17/19
10/17
18:49
10/17/19
18:49
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MRTN

Marten Transport

$21.52

0.31 (1.46%)

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

ETFC

E-Trade

$39.04

0.02 (0.05%)

WAL

Western Alliance

$46.24

0.53 (1.16%)

TEAM

Atlassian

$122.43

-1.91 (-1.54%)

PRTK

Paratek Pharmaceuticals

$3.46

0.05 (1.47%)

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

EXPO

Exponent

$70.82

1.34 (1.93%)

WDFC

WD-40

$182.75

2.41 (1.34%)

VICR

Vicor Corporation

$32.78

1.16 (3.67%)

OZK

Bank OZK

$28.32

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 22

    Nov

ARWR

Arrowhead

$36.61

2.11 (6.12%)

, AMGN

Amgen

$203.60

0.32 (0.16%)

18:43
10/17/19
10/17
18:43
10/17/19
18:43
Hot Stocks
Arrowhead CEO: We can silence a single gene »

In an interview on…

ARWR

Arrowhead

$36.61

2.11 (6.12%)

AMGN

Amgen

$203.60

0.32 (0.16%)

JNJ

Johnson & Johnson

$136.20

1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

SXT

Sensient

$66.57

0.4 (0.60%)

18:32
10/17/19
10/17
18:32
10/17/19
18:32
Hot Stocks
Sensient raises quarterly dividend 8.3% to 39c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

T

AT&T

$37.82

0.03 (0.08%)

18:31
10/17/19
10/17
18:31
10/17/19
18:31
Periodicals
HBO Max to stream Studio Ghibli films, Reuters says »

AT&T's upcoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

OMAB

OMA

$52.10

0.47 (0.91%)

18:19
10/17/19
10/17
18:19
10/17/19
18:19
Earnings
OMA reports Q3 net income MXN858M vs. MXN725M last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MAR

Marriott

$120.57

-0.55 (-0.45%)

18:13
10/17/19
10/17
18:13
10/17/19
18:13
Periodicals
Marriott near deal for Elegant Hotels valued up to GBP1 / shr, Bloomberg says »

The report states that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

, SPX

S&P 500

$0.00

(0.00%)

18:08
10/17/19
10/17
18:08
10/17/19
18:08
General news
NY Fed's Williams Condition in money markets highly volatile over past month »

Williams says:…

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.20

-0.45 (-1.23%)

17:47
10/17/19
10/17
17:47
10/17/19
17:47
Periodicals
GM strike to continue until deal with UAW is ratified, WSJ says »

United Auto Workers union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.82

0.03 (0.08%)

17:37
10/17/19
10/17
17:37
10/17/19
17:37
Periodicals
AT&T, Elliott Management in talks to resolve activist campaign, WSJ reports »

AT&T is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

WAL

Western Alliance

$46.24

0.53 (1.16%)

17:27
10/17/19
10/17
17:27
10/17/19
17:27
Earnings
Western Alliance reports Q3 EPS $1.24, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

RNLSY

Renault

$0.00

(0.00%)

17:25
10/17/19
10/17
17:25
10/17/19
17:25
Downgrade
Renault rating change at Deutsche Bank »

Renault downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$19.10

0.63 (3.41%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Hot Stocks
Park West Management reports 5.1% passive stake in Lovesac »

Park West Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

T

AT&T

$37.82

0.03 (0.08%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Periodicals
Breaking Periodicals news story on AT&T »

AT&T in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

ATVI

Activision Blizzard

$55.60

0.01 (0.02%)

17:16
10/17/19
10/17
17:16
10/17/19
17:16
Hot Stocks
Activision says Call of Duty to get 'battle pass' feature, 'not loot box system' »

Activision's Call of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:11
10/17/19
10/17
17:11
10/17/19
17:11
Hot Stocks
Brandywine Realty sees FY19 year-end core occupancy at 94%-95% »

Also sees FY20 year-end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:10
10/17/19
10/17
17:10
10/17/19
17:10
Hot Stocks
Brandywine Realty reports Q3 same-store net operating income up 0.6% »

Reports Q3 occupancy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:09
10/17/19
10/17
17:09
10/17/19
17:09
Earnings
Brandywine Realty sees FY20 initial FFO $1.41-$1.51, consensus $1.46 »

Sees FY20 same-store net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

17:08
10/17/19
10/17
17:08
10/17/19
17:08
Earnings
Gildan Activewear cuts FY19 adj. EPS view to $1.65-$1.70 from $1.95-$2.00 »

Consensus $1.97. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty narrows FY19 FFO guidance to $1.41-$1.43 from $1.40-$1.44 

Consensus $1.42.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty reports Q3 FFO 36c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.